Table 2.
Summary of univariate and multivariate on PFS analysis
| Parameters | No. | Median PFS | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| (95% CI) | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age | ||||||
| ＜47 | 15 | 7.7 (6.9–8.5) | 0.6 (0.3–1.3) | 0.21 | ||
| ≥47 | 16 | 7.4 (3.4–11.5) | ||||
| DFI | ||||||
| ＜2 years | 15 | 7.7 (5.2–10.2) | 0.7 (0.3–1.4) | 0.3 | ||
| ≥2 years | 15 | 7.7 (6.9–8.6) | ||||
| No. of metastatic sites | ||||||
| 1 | 9 | 8.9 (6.1–11.6) | 1.6 (0.7–4.0) | 0.25 | ||
| ≥2 | 22 | 7.0 (5.0–9.0) | ||||
| Liver metastasis | ||||||
| Yes | 5 | 5.2 (4.5–5.8) | 3.6 (1.2–10.7) | 0.02 | 3.49 (1.06–11.43) | 0.039 |
| No | 25 | 7.7 (7.1–8.4) | ||||
| LI | ||||||
| ＜0.56 | 16 | 8.1 (6.3–9.8) | 3.3 (1.5–7.3) | 0.003 | 4.81 (1.16–19.91) | 0.03 |
| ≥0.56 | 15 | 5.2 (4.1–6.2) | ||||
| SUV max | ||||||
| ＜4.31 | 15 | 7.9 (7.6–8.3) | 1.2 (0.6–2.6) | 0.576 | ||
| ≥4.31 | 16 | 6.0 (3.4–8.6) | ||||
| MTV(mL) | ||||||
| ＜1.25 | 15 | 7.9 (6.6–9.3) | 0.9 (0.4–2.1) | 0.92 | ||
| ≥1.25 | 16 | 7.0(4.1–9.8) | ||||
| TLG (g) | ||||||
| ＜3.54 | 16 | 8.1 (6.2–9.9) | 2.6 (1.2–5.8) | 0.014 | 2.15 (0.54–8.54) | 0.28 |
| ≥3.54 | 15 | 5.9 (3.6–8.4) | ||||
Abbreviations: PFS, progression-free survival; DFI, disease-free interval; ECOG, eastern cooperative oncology group; LI, low index; SUV, standard uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.